- Wilmington PharmaTech is investing $50 million to expand its Delaware campus, adding two 10,000-liter reactor suites to increase API manufacturing capacity.
- The expansion is expected to be operational by Q3 2027 and will approximately double both reactor capacity and site workforce.
Wilmington PharmaTech has announced a $50 million investment to expand its API manufacturing campus in Newark, Delaware, aiming to increase domestic production capacity for small molecule active pharmaceutical ingredients.
The expansion will add two 10,000-liter reactor suites, enhancing the company’s ability to support commercial-scale production of small molecule APIs and peptides. The new capacity is expected to come online in the third quarter of 2027. Upon completion, the company anticipates approximately doubling both its reactor capacity and workforce at the site.
The investment represents the second phase of Wilmington’s multi-year strategy to expand U.S.-based contract manufacturing capabilities. It follows the recent addition of dedicated suites for highly potent API (HPAPI) production, supporting demand for complex chemistry and domestic supply chains.
Wilmington stated that the expansion is intended to meet increasing demand for U.S.-based manufacturing and strengthen its position as a partner for biopharmaceutical companies seeking scalable API production.
“Over the past decade, Wilmington has been among the few companies to actively invest in cGMP API manufacturing capacity in the U.S., including the recent addition of two new commercial-scale high-potency API suites.”
Hui-Yin “Harry” Li, Ph.D., founder and CEO of Wilmington PharmaTech
